Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 6/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PDE1A | P54750 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924045 | 0.99 | TLR8 (0.36) | TLR8PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL924681 | 0.90 | ALDH1A1 (0.45) | TLR8ALDH1A1POLBKMT2AHSD17B10 | |
| SCHEMBL923784 | 0.87 | ALDH1A1 (0.34) | TLR8ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL923794 | 0.79 | C1S (0.35) | ALDH1A1HSD17B10 | |
| SCHEMBL12907255 | 0.70 | SMN1; SMN2 (0.46) | ALDH1A1KMT2AGRM2CYP2C19 | |
| SCHEMBL924363 | 0.69 | CYP1A2 (0.51) | ALDH1A1KMT2AHSD17B10CYP2C19 | |
| SCHEMBL923585 | 0.67 | ALDH1A1 (0.42) | TLR8PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29068022 | 0.67 | GRM2 (0.43) | TLR8PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL924488 | 0.67 | ALDH1A1 (0.42) | TLR8PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27845254 | 0.66 | TLR8 (0.42) | TLR8PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102632-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| EP-2250156-B1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-20140100235-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| US-8637522-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20110015210-A1 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PAATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2250156-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009109259-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100235-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, IAPP | TLR8 2671/4885PDE4A 267/4885PDE4B 604/4885 |
| US-20110015210-A1 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GLP1R, IAPP, INSR | TLR8 3057/4885PDE4A 236/4885PDE4B 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.